Profusa Inc. and Bio Insights LLC amended their April 2026 Asset Purchase Agreement for the PanOmics Platform by removing a provision requiring issuance of 12% equity to management for CEO/CFO retention. The modification suggests potential recalibration of deal economics or management compensation structure.